PSS35 - SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Abstract
Authors
P.A. Laires C. Silva J. Esparteiro
P.A. Laires C. Silva J. Esparteiro
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now